ProAgio

N/A

Report date: 2024/06/17 20:00:40

Base Information

Drug NameProAgio
Drug Alias NameN/A
ClassificationBiologics > Protein drugs
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteUniversity Of Alabama At BirminghamProDa BioTech LLC
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsColorectal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A